Clair Health, which is developing what it describes as the first noninvasive continuous hormone monitor for women, has raised $11.6 million led by Khosla Ventures with participation from a16z speedrun, Brydge Club, AI in Health Fund, Cartan Capital, and angel investors including 23andMe founder Anne Wojcicki. The company has accumulated a 25,000+ person waitlist ahead of its planned November 2026 wearable launch.
The jewelry-inspired wrist device uses 10 biosensors and 130+ proprietary biomarkers to continuously monitor estrogen, progesterone, LH, and FSH without blood draws, urine tests, or needles. In beta testing, Clair says it has identified nine distinct sub-phases of the female hormone cycle, where women have traditionally been told there are four.
“Wearables are great at monitoring metrics like HRV, sleep, step count, and breathing rate,” said co-founder Jenny Duan. “What they’ve missed is that all of these signals for women are being shaped by their hormones. The data has always been there; we just haven’t had something to read it until now.”
The company positions itself in contrast to what it describes as legacy wearable companies retrofitting women’s health features onto devices built on assumed 28-day cycles or male physiology. Clair serves women across every stage of hormonal health – fertility tracking and conception timing, hormonal conditions like PMOS, fitness training and recovery, and perimenopause.
Co-founded by Stanford graduates Jenny Duan and Abhinav Agarwal, the funding will accelerate the November wearable launch and fund continued research.
